Skinvisible, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019
August 16, 2019 at 01:19 pm EDT
Share
Skinvisible, Inc. announced earnings results for the second quarter ended June 30, 2019. For the second quarter, the company announced sales was USD 12,717 compared to USD 22,284 a year ago. Operating loss was USD 139,296 compared to USD 131,309 a year ago. Net loss was USD 583,011 compared to USD 396,664 a year ago. Basic loss per share from continuing operations was USD 0.21 compared to USD 0.14 a year ago. For the half year, sales was USD 21,084 compared to USD 37,916 a year ago. Operating loss was USD 285,388 compared to USD 305,875 a year ago. Net loss was USD 926,110 compared to USD 300,134 a year ago. Basic loss per share from continuing operations was USD 0.32 compared to USD 0.11 a year ago.
Skinvisible, Inc., through its wholly owned subsidiary Skinvisible Pharmaceuticals Inc., is a pharmaceutical research and development (R&D) company. The Company is engaged in developing and patenting a polymer delivery system, Invisicare and formulated over forty topical skin products. The Company's product, Pivotal, is a patented polymer delivery system technology Invisicare. Invisicare is a patented polymer delivery system that enhances the delivery of active ingredients for topically applied skin care products. Its patented technology has a formula and process for combining active ingredients with a delivery system that extends the duration of time the product remains on the skin and active. Invisicare is specifically formulated to carry water-insoluble active and certain cationic active ingredients in water-based products without the use of alcohol, silicones, waxes, or other organic solvents.
SKINVISIBLE, INC. 
